What is the level of liabilities of Dongkook Pharmaceutical Co this year?
Dongkook Pharmaceutical Co has a debt balance of 294.84 B KRW this year.
In 2024, Dongkook Pharmaceutical Co's total liabilities amounted to 294.84 B KRW, a 10.68% difference from the 266.39 B KRW total liabilities in the previous year.
Dongkook Pharmaceutical Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Dongkook Pharmaceutical Co's financial stability, operational efficiency, and long-term viability.
By comparing Dongkook Pharmaceutical Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Dongkook Pharmaceutical Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Shifts in Dongkook Pharmaceutical Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Dongkook Pharmaceutical Co has a debt balance of 294.84 B KRW this year.
The liabilities of Dongkook Pharmaceutical Co have increased by 10.68% increased compared to the previous year.
High liabilities can pose a risk for investors of Dongkook Pharmaceutical Co, as they can weaken the company's financial position and impair its ability to meet its obligations.
Low liabilities mean that Dongkook Pharmaceutical Co has a strong financial position and is able to meet its obligations without overburdening its finances.
An increase in liabilities of Dongkook Pharmaceutical Co can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
A decrease in the liabilities of Dongkook Pharmaceutical Co can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
Some factors that can influence the liabilities of Dongkook Pharmaceutical Co include investments, acquisitions, operating costs, and sales development.
The liabilities of Dongkook Pharmaceutical Co are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
To change its liabilities, Dongkook Pharmaceutical Co can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
Over the past 12 months, Dongkook Pharmaceutical Co paid a dividend of 180 KRW . This corresponds to a dividend yield of about 1.03 %. For the coming 12 months, Dongkook Pharmaceutical Co is expected to pay a dividend of 196.06 KRW.
The current dividend yield of Dongkook Pharmaceutical Co is 1.03 %.
Dongkook Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of January, January, January, January.
Dongkook Pharmaceutical Co paid dividends every year for the past 15 years.
For the upcoming 12 months, dividends amounting to 196.06 KRW are expected. This corresponds to a dividend yield of 1.12 %.
Dongkook Pharmaceutical Co is assigned to the 'Health' sector.
To receive the latest dividend of Dongkook Pharmaceutical Co from 4/19/2024 amounting to 180 KRW, you needed to have the stock in your portfolio before the ex-date on 12/27/2023.
The last dividend was paid out on 4/19/2024.
In the year 2023, Dongkook Pharmaceutical Co distributed 180 KRW as dividends.
The dividends of Dongkook Pharmaceutical Co are distributed in KRW.
Our stock analysis for Dongkook Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dongkook Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.